EMEA-002303-PIP01-17-M03 - paediatric investigation plan

Etripamil

Key facts

• Active Substance:
  Etripamil
• Therapeutic area:
  Cardiovascular diseases
• Decision number:
  P/0349/2022
• PIP number:
  EMEA-002303-PIP01-17-M03
• Pharmaceutical form(s):
  Nasal spray (solution)
• Condition(s) / indication(s):
  Treatment of supraventricular arrhythmias
• Route(s) of administration:
  Intranasal use
• Contact for public enquiries:

  Milestone Pharmaceuticals Inc.

  Tel. [phone]; E-mail: [e-mail]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  10/08/2022

Decision

P/0349/2022 : EMA decision of 10 August 2022 on the acceptance of a modification of an agreed paediatric investigation plan for etripamil (EMEA-002303-PIP01-17-M03)

AdoptedReference Number: EMA/672888/2022